Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series
Seyed Mohammad Reza Hashemian, Rasoul Aliannejad, Morteza Zarrabi, et al.
Stem Cell Research & Therapy (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 176

Showing 1-25 of 176 citing articles:

Stem cell-based therapy for human diseases
Duc M. Hoang, Phuong T. Pham, Trung Q. Bach, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 589
Carbon-Based Nanomaterials: Promising Antiviral Agents to Combat COVID-19 in the Microbial-Resistant Era
Ángel Serrano‐Aroca, Kazuo Takayama, Alberto Tuñón-Molina, et al.
ACS Nano (2021) Vol. 15, Iss. 5, pp. 8069-8086
Open Access | Times Cited: 161
Potential therapeutic options for COVID-19: an update on current evidence
Zahra Niknam, Ameneh Jafari, Ali Golchin, et al.
European journal of medical research (2022) Vol. 27, Iss. 1
Open Access | Times Cited: 136
Nebulized exosomes derived from allogenic adipose tissue mesenchymal stromal cells in patients with severe COVID-19: a pilot study
Yinggang Zhu, Mengmeng Shi, Antoine Monsel, et al.
Stem Cell Research & Therapy (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 108
Allogeneic vs. autologous mesenchymal stem/stromal cells in their medication practice
Chenghai Li, Hua Zhao, Linna Cheng, et al.
Cell & Bioscience (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 105
Allogenic mesenchymal stromal cells and their extracellular vesicles in COVID-19 induced ARDS: a randomized controlled trial
Morteza Zarrabi, Mohammad Amin Shahrbaf, Masoumeh Nouri, et al.
Stem Cell Research & Therapy (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 39
Safety and efficacy of human umbilical cord-derived mesenchymal stem cells in COVID-19 patients: A real-world observation
Siyu Wang, Tao Yang, Tiantian Li, et al.
Chinese Medical Journal (2025)
Open Access | Times Cited: 1
Human mesenchymal stem cells treatment for severe COVID-19: 1-year follow-up results of a randomized, double-blind, placebo-controlled trial
Lei Shi, Xin Yuan, Weiqi Yao, et al.
EBioMedicine (2021) Vol. 75, pp. 103789-103789
Open Access | Times Cited: 86
Mesenchymal stem cell therapy for severe COVID-19
Lei Shi, Lifeng Wang, Ruonan Xu, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 85
Cell therapy in patients with COVID-19 using Wharton’s jelly mesenchymal stem cells: a phase 1 clinical trial
Mahshid Saleh, Amir Abbas Vaezi, Rasoul Aliannejad, et al.
Stem Cell Research & Therapy (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 72
Mesenchymal Stem/Stromal Cells Derived from Human and Animal Perinatal Tissues—Origins, Characteristics, Signaling Pathways, and Clinical Trials
Magdalena Kulus, Rafał Sibiak, Katarzyna Stefańska, et al.
Cells (2021) Vol. 10, Iss. 12, pp. 3278-3278
Open Access | Times Cited: 57
Mesenchymal Stromal Cells for Enhancing Hematopoietic Engraftment and Treatment of Graft-Versus-Host Disease, Hemorrhages and Acute Respiratory Distress Syndrome
Olle Ringdén, Guido Moll, Britt Gustafsson, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 57
Mesenchymal stem cell treatment for COVID-19
Ruonan Xu, Zhiqian Feng, Fu‐Sheng Wang
EBioMedicine (2022) Vol. 77, pp. 103920-103920
Open Access | Times Cited: 55
Mesenchymal stromal cell therapy for COVID-19-induced ARDS patients: a successful phase 1, control-placebo group, clinical trial
Najmeh Kaffash Farkhad, Alireza Sedaghat, Hamidreza Reihani, et al.
Stem Cell Research & Therapy (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 46
Safety and long-term improvement of mesenchymal stromal cell infusion in critically COVID-19 patients: a randomized clinical trial
Cármen Lúcia Kuniyoshi Rebelatto, Alexandra Cristina Senegaglia, Cláudio Luciano Franck, et al.
Stem Cell Research & Therapy (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 44
SARS-CoV-2 Infection and Lung Regeneration
Fuxiaonan Zhao, Qingwen Ma, Qing Yue, et al.
Clinical Microbiology Reviews (2022) Vol. 35, Iss. 2
Open Access | Times Cited: 42
The safety and efficacy of mesenchymal stromal cells in ARDS: a meta-analysis of randomized controlled trials
Shou Zhen Wang, Yiming Li, Bingqing Wang, et al.
Critical Care (2023) Vol. 27, Iss. 1
Open Access | Times Cited: 31
Umbilical Cord Blood Transplantation: Connecting Its Origin to Its Future
Gabriela Sanchez‐Petitto, Katayoun Rezvani, May Daher, et al.
Stem Cells Translational Medicine (2023) Vol. 12, Iss. 2, pp. 55-71
Open Access | Times Cited: 23
A Mesenchymal stem cell Aging Framework, from Mechanisms to Strategies
Hongqing Zhao, Houming Zhao, Shuaifei Ji
Stem Cell Reviews and Reports (2024) Vol. 20, Iss. 6, pp. 1420-1440
Closed Access | Times Cited: 7
Mesenchymal stem cells and their derived exosomes to combat Covid–19
Maryam Yousefi Dehbidi, Nima Goodarzi, Mohammad H. Azhdari, et al.
Reviews in Medical Virology (2021) Vol. 32, Iss. 2
Open Access | Times Cited: 46
Microfluidic Tools for Enhanced Characterization of Therapeutic Stem Cells and Prediction of Their Potential Antimicrobial Secretome
Pasquale Marrazzo, Valeria Pizzuti, Silvia Zia, et al.
Antibiotics (2021) Vol. 10, Iss. 7, pp. 750-750
Open Access | Times Cited: 40
Spotlight on therapeutic efficiency of mesenchymal stem cells in viral infections with a focus on COVID-19
Saman Yasamineh, Hesam Ghafouri Kalajahi, Pooneh Yasamineh, et al.
Stem Cell Research & Therapy (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 35
Bone Marrow-Derived Mesenchymal Stromal Cell Therapy in Severe COVID-19: Preliminary Results of a Phase I/II Clinical Trial
Céline Gregoire, Nathalie Layios, Bernard Lambermont, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 35
Anti‐SARS‐CoV‐2 effect of extracellular vesicles released from mesenchymal stem cells
Somchai Chutipongtanate, Supasek Kongsomros, Nutkridta Pongsakul, et al.
Journal of Extracellular Vesicles (2022) Vol. 11, Iss. 3
Open Access | Times Cited: 34
Mesenchymal stem cell-based treatments for COVID-19: status and future perspectives for clinical applications
Lijun Chen, Jingjing Qu, Farhin Shaheed Kalyani, et al.
Cellular and Molecular Life Sciences (2022) Vol. 79, Iss. 3
Open Access | Times Cited: 33
Page 1 - Next Page

Scroll to top